Efficacy and Safety of Cipros 20 Association on Dyslipidemia Treatment

Last updated: January 7, 2026
Sponsor: EMS
Overall Status: Completed

Phase

3

Condition

N/A

Treatment

Cipros 20 association

Crestor 20 mg

Clinical Study ID

NCT03540355
EMS0717
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to evaluate the efficacy of Cipros 20 association in the treatment of dyslipidemia treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Participants of both sexes, aged 18 years or more;

  • Participants with the diagnosed of dyslipidemia and with high or very highcardiovascular risk, according to the Brazillian Guidelines on Dyslipidemia andPrevention of Atherosclerosis;

  • Signed consent.

Exclusion

Exclusion Criteria:

  • Using medications that may interfere with the metabolism or serum levels oftriglycerides;

  • Any clinical and laboratory findings that, in the judgment of the investigator, mayinterfere with the safety of research participants;

  • Presence of concomitant cardiovascular disease, renal failure and hepatic failure;

  • Decompensated diabetes;

  • Current smoking;

  • History hypersensitivity to the active ingredients used in the study;

  • Pregnancy or risk of pregnancy and lactating patients;

  • History of alcohol abuse or illicit drug use;

  • Participation in clinical trial in the year prior to this study.

Study Design

Total Participants: 406
Treatment Group(s): 2
Primary Treatment: Cipros 20 association
Phase: 3
Study Start date:
March 02, 2021
Estimated Completion Date:
January 23, 2025

Connect with a study center

  • Allergisa

    Campinas, São Paulo
    Brazil

    Site Not Available

  • Allergisa

    Campinas 3467865, São Paulo 3448433
    Brazil

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.